Evidence map›Paper›PMID 42327580›Full record

ReviewJournal of Cancer2026

Emerging Oncolytic Viruses: Beyond Adenoviruses and Herpes Simplex Virus.

Santosh Chokkakula, Chengliang Yin, Bing Yang, Siomui Chong, Balaji Pathakumari, Yi-Quan Zhang, Pangi Vijaya Nirmala, Khin Wee Lai, Bommireddy Naveen, Quan Tang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Santosh ChokkakulaDepartment of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Chungbuk, 28644, South Korea.
Chengliang YinDepartment of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.
Bing YangDepartment of Medical and Nursing Science, International College, Krirk University, Bangkok 10220, Thailand.
Siomui ChongDepartment of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518053, China.
Balaji PathakumariDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Yi-Quan ZhangDepartment of Cell Biology, College of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Pangi Vijaya NirmalaSchool of Life & Health Sciences Adikavi Nannaya University Rajahmundry, Andhra Pradesh India, 533296, India.
Khin Wee LaiDepartment of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, Kuala Lumpur, 50603, Malaysia.
Bommireddy NaveenDepartment of Chemical and Biological Engineering, Gachon University, Seongnam-Si, Gyeonggi-do, Republic of Korea.
Quan TangResearch Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oncolytic virotherapy represents an innovative therapeutic modality in oncology, exploiting the selective tropism of viruses to target and eradicate malignant cells. Unlike conventional cancer treatments such as chemotherapy and radiotherapy, oncolytic viruses (OVs) exhibit a dual mechanism of action: direct tumor cell lysis and potent immune activation. This approach transforms tumors into

Indexed as

cancer treatmentimmune responseimmunogenic cell death (ICD)metastatic melanomaoncolytic virotherapyoncolytic virusestalimogene laherparepvectumor cell lysis

Identifiers

PMID42327580
PMCPMC13280627

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.